NAD+ Supplements Show Promise in Early Studies but Face Absorption and Cost Hurdles
Similar Articles
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Daily Multivitamin Use Linked to Slower Biological Aging in Older Adults
NIH Bridge Funding Sustains Alzheimer's Research Network After Grant Rejection
Specific Diets Linked to Reduced Biological Age in Older Adults, Study Finds
Anti-Amyloid Drugs Show Limited Benefit for Early Alzheimer's, Carry Side Effects
Research into boosting levels of the age-related molecule NAD+ (Nicotinamide adenine dinucleotide) is progressing, with small human studies showing potential benefits for specific conditions. However, significant questions remain about the effectiveness and safety of popular delivery methods like oral supplements and intravenous infusions. The cost of these interventions varies widely, and product quality can be inconsistent.
Facts First
- NAD+ levels decline with age, a process linked to age-related disease risks in preclinical models.
- Small human trials show promise for specific groups, including people with prediabetes, Parkinson's disease, and peripheral artery disease.
- Oral supplements may be poorly absorbed, and independent testing reveals variability in product quality.
- Intravenous infusions are costly and may be inefficient, with a pilot study linking them to gastrointestinal side effects.
- Safety research is ongoing, with some mouse models suggesting a potential link to tumor growth that hasn't been seen in humans.
What Happened
Nicotinamide adenine dinucleotide (NAD+) is a molecule involved in mitochondrial energy production and DNA repair, and its levels decline as humans age. The body produces NAD+ from dietary precursors like vitamin B3 and tryptophan. Research has moved from preclinical studies in rodents to human clinical trials, primarily studying precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Small-scale human studies have shown promising data for specific populations, including women with prediabetes, patients with Parkinson's disease, and those with peripheral artery disease.
Why this Matters to You
If you are considering interventions to support healthy aging, you now have more information on the potential and limitations of NAD+ boosting. Oral supplements, priced between $30 and $80, may be degraded in the gut and poorly absorbed. More expensive intravenous infusions at wellness clinics, costing $200 to over $1,000 per session, may be inefficient at increasing cellular NAD+ levels and could cause moderate to severe abdominal cramping, diarrhea, nausea, and vomiting. This suggests you may need to carefully evaluate the cost versus the potential, and still uncertain, benefit of different delivery methods.
What's Next
Research is likely to continue refining delivery methods and understanding long-term effects. Scientists may focus on developing more efficient ways to boost cellular NAD+ levels, given the challenges with current oral and intravenous routes. Further human studies are needed to confirm the promising early results in specific disease populations and to thoroughly investigate safety concerns, including the potential link to tumor growth suggested by some mouse models. Consumer awareness of product quality variability may also drive demand for more standardized testing.